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The HCV-IRES sequence is vital for both protein translation and genome replication and serves as a
potential target for anti-HCV therapy. We constructed a series of anti-HCV group I introns (αHCV-GrpIs)
to attack conserved target sites within the HCV IRES. These αHCV-GrpIs were designed to mediate a
trans-splicing reaction that replaces the viral RNA genome downstream of the 50 splice site with a 30
exon that encodes an apoptosis-inducing gene. Pro-active forms of the apoptosis inducing genes BID,
Caspase 3, Caspase 8, or tBax were modiﬁed by incorporation of the HCV NS5A/5B cleavage sequence in
place of their respective endogenous cleavage sites to ensure that only HCV infected cells would undergo
apoptosis following splicing and expression. Huh7.5 cells transfected with each intron were challenged
at MOI 0.1 with HCV-Jc1FLAG2 which expresses a Gaussia Luciferase (GLuc) marker. Virus-containing
supernatants were then assayed for GLuc expression as a measure of viral replication inhibition. Cellular
extracts were analyzed for the presence of correct splice products by RT-PCR and DNA sequencing. We
also measured levels of Caspase 3 activity as a means of quantifying apoptotic cell death. Each of these
αHCV-GrpI introns was able to correctly splice their 30 apoptotic exons onto the virus RNA genome at the
targeted Uracil, and resulted in greater than 80% suppression of the GLuc marker. A more pronounced
suppression effect was observed with TCID50 virus titrations, which demonstrated that these αHCV-
GrpIs were able to suppress viral replication by more than 2 logs, or greater than 99%. Robust activation
of the apoptotic factor within the challenged cells was evidenced by a signiﬁcant increase of Caspase
3 activity upon viral infection compared to non-challenged cells. This novel genetic intervention tool
may prove beneﬁcial in certain HCV subjects.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Hepatitis C Virus (HCV) affects more than 170 million people
worldwide, or 3% of the world population (Perz et al., 2006), with
4 million new cases and more than 300,000 deaths per year (Bukh,
2012). Clinical conditions of the disease range from an asymptomatic
carrier state to persistent infections. Of those individuals infected, 70%
will develop chronic HCV infections, and 20% of chronic infections will
progress to cirrhosis and terminal hepatocellular carcinoma (Bradley,
2000; Lauer and Walker, 2001; Seeff, 2002; Hoofnagle, 1997). There
are currently no vaccines available to the public to prevent HCV due to
the high genetic variability of the virus and its ability to escape host
immune defenses (Di Lorenzo et al., 2011).
The current standard of care (SOC) treatments may include a
combination of pegylated interferon-α and ribavirin (Christie and
Chapman, 1999) and direct acting antivirals such as Sofosbuvir and
Simeprevir (Belousova et al., 2015). The drug combination has
unfavorable side effects and may ultimately lead to drug resistance
and relapse. One of the main reasons may be attributed to the
generation of quasispecies genome diversity common for HCV infec-
tions, a phenomenon that results in infection by a swarm of micro-
variants derived from a predominant “master sequence” within an
individual host (Bukh et al., 1995). Quasispecies are more prominent in
the setting of persistent infections and may be responsible for drug
treatment failures (Farci et al., 2000; Domingo and Gomez, 2007).
Quasispecies result from the high error rate of the non-proofreading
HCV RNA-dependent RNA polymerase (RdRp) leading to continuous
production of mutated virus sequences which is one mechanism the
virus employs to escape immune system defense (Carmichael, 2002).
This warrants a continued intensive search for alternative antiviral
approaches to combating HCV.
HCV is a plus-strand RNA virus of the Hepacivirus genus, having a
9600 nt long genome encoding a single ORF ﬂanked by highly
conserved 50 and 30 untranslated regions (UTRs) (Takamizawa et al.,
1991). The ORF encodes a single polyprotein that is modiﬁed post-
translationally by both cellular and viral proteases to produce 3 struc-
tural (C, E1, E2) and 7 non-structural (p7, NS2, NS3, NS4A, NS4B, NS5A,
and NS5B) proteins (Fauvelle et al., 2013). The 50 UTR of the viral RNA
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contains an internal ribosome entry site (IRES) that is highly
conserved among most known HCV quasispecies (Brown et al.,
1992). The 50 UTR of HCV facilitates viral replication and mediates
cap-independent viral protein translation by acting as a scaffold and
recruiting multiple protein factors during the initiation of transla-
tion upon early infection (Rosenberg, 2001; Kieft et al., 1999; Friebe
and Bartenschlager, 2002). Because the IRES serves a crucial
function for viral infection and propagation and is therefore highly
conserved, it represents an ideal target for anti-HCV approaches
employing nucleic acid homologies such as trans-splicing group I
introns (Ryu et al., 2003).
Trans-splicing group I introns derived from the cis-splicing
group I intron of Tetrahymena thermophila mediate RNA splicing
through two successive transesteriﬁcation steps (Cech, 1991). First,
the intron recognizes a speciﬁc uracil on the target RNA during
complementary base pairing with the surrounding sequence. The
target RNA is then cleaved at that uracil, and the intron-attached 30
exon is cleaved from the group I intron and appended onto the
cleaved target RNA to create a product RNA. If that product is
capable of translation it will express a new protein encoded by the
sequence of the 30 exon (Long et al., 2003). Group I introns have
been used successfully in a number of anti-viral applications
including targeting of Dengue Fever virus (Carter et al., 2010),
HCV (Ryu et al., 2003), and HIV (Kohler et al., 1999) genomes, and
in posttranscriptional gene manipulations including the restora-
tion of wild-type p53 activity in three cancerous cell lines (Shin
et al., 2004) and the repair of sickle β-globin mRNAs in erythrocyte
precursors (Lan et al., 1998).
In this report we describe the construction and activity analysis of
a series of anti-HCV group I introns (αHCV-GrpIs). These αHCV-GrpIs
were designed to be more effective than conventional group I introns
by extending both the External Guide Sequence (EGS) to increase the
target base pairing speciﬁcity, and the Internal Guide Sequence (IGS)
to help stabilize the base pairing at the catalytic site (Kohler et al.,
1999). Apoptosis-inducing gene sequences were incorporated as 30
exons to induce cell death upon successful splicing.
We verify the functional characteristics of two αHCV-GrpIs con-
structed to target conserved sequences within the IRES surrounding
U329 of stem loop IIIf and U343 of stem loop IV. These αHCV-GrpIs
mediate trans-splicing reactions that cleave the HCV RNA genome at
the designated uracils and append a 30 exon composed of sequences
that complete the downstream region of the HCV IRES, start codon
AUG, and N-terminal coding sequence of the HCV core protein, all
of which are mandatory for efﬁcient initiation of IRES-dependent
translation. These reconstituted IRES sequences are followed by one of
the apoptosis-inducing genes BID, Caspase 3, Caspase 8 or a truncated
form of Bax calledΔN Bax (abbreviated as tBax in this publication). To
prevent unintended expression of these apoptotic genes and to inc-
rease the speciﬁcity of activity for HCV infections, these genes are
incorporated in their pro-active forms, replacing their respective
endogenous cleavage sites with the HCV NS5A/5B cleavage sequence
recognized by the virus protease NS3/4A (Hsu et al., 2003). Using this
strategy, the functional “active” form of the pro-apoptotic gene is
produced only upon correct trans-splicing and in the presence of the
active HCV protease, ensuring that only infected cells can undergo
apoptosis. This successful genetic approach may provide a useful tool
for intervention strategies against HCV.
Results
Target site selection
We retrieved all known HCV quasispecies from The Los Alamos
HCV Sequence Database (Kuiken et al., 2005) and aligned them in
ClustalX. Intron design was focused to target the IRES sequence
located in the 50 region of the virus genome since this structure is
highly conserved among HCV quasispecies (Fig. 1A). Initially, we
constructed and tested several group I introns targeting multiple sites
throughout the IRES, but later narrowed down our focus to those that
attack target sites at the very 30 end of the IRES. Our initial results
demonstrated that introns targeting stem loops IIIa and IIIb did not
completely prohibit the function of the IRES to translate the ﬁreﬂy
luciferase gene in the artiﬁcial target. In contrast, introns that were
designed to target the very 30 end of the IRES were able to knock
down the IRES translation by 95% (Fig. 1C). Two target sites, U329 and
U343 (Fig. 1B), were selected for further experiments. U329 is located
in the conserved pseudoknot (stem loop IIIf) region which is part of
the 40S binding domain crucial for viral translation (Wang et al., 1995;
Lytle et al., 2002). U343 is part of the AUG start codon (stem loop IV)
of the core-coding sequence and is positioned at the P site during
translation initiation (Ji et al., 2004).
Design of anti-HCV group I intron targeting conserved IRES sequences
The group I intron trans-splicing mechanism has been described
extensively (Carter et al., 2010; Kohler et al., 1999). Our optimized
αHCV-GrpIs incorporate amore extensive complementary base-pairing
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Fig. 1. Structure of HCV IRES. Adapted from Tumban et al. (2009). (A) Complete IRES construct containing stem-loop I–IV. The AUG start codon of the core protein is
bordered; (B) Stem-loop IIIf and IV enlarged to show target sites for I19 and I20 at U329 and U343 (circled), respectively; (C) FLuc assay demonstrating that the intron
targeting stem loop IV (I-SL IV) inhibited a near-complete IRES translation compared to those targeting stem loop IIIa (I-SL IIIa) and IIIb (I-SL-IIIb).
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between the EGS and IGS and the virus genomic RNA to improve both
speciﬁcity and splicing activities at the targeted uracil (Fig. 2: step A).
The EGS can be of nearly any practical length from as short as 5 bases
without compromising the splicing efﬁcacy (Byun et al., 2003),
although longer sequences may decrease the efﬁciency of the reaction
due to internal interactions and/or non-speciﬁc binding to non-target
RNAs (Ban et al., 2009). The emphasis on the design and addition of the
EGS reduce potential illegitimate binding of the intron to non-target
RNA that may result in unintentional activation of the apoptosis in non-
HCV infected cells. The ability of our introns to attack target single-
stranded motifs in the secondary structure of the IRES was demon-
strated by splice product detection.
The splicing reaction relies on the formation of the P1 and P10
helices between the target RNA and the group I intron. The IGS
participates in the formation of the P1 helix that spans the reactive
uracil required for proper trans-splicing mechanism (Kohler et al.,
1999). Nucleophilic attack by the 30-OH of a free exogenous
guanosine cleaves the phosphate backbone of the target RNA
molecule 30 of the P1 helix-embedded uracil. The splicing reaction
is facilitated allowing the intron to form a P10 helix that brings the
30exon into proximity with the P1-attached 30-OH, which later
attacks the phosphate backbone upstream of the group I intron-
attached 30 exon to complete the trans-splicing reaction (Fig. 2:
step B). To insure expression from the spliced RNA, we incorpo-
rated sequences that reconstituted the IRES sequence from the
splice target in the HCV genome through the ﬁrst 30 nt of the HCV
core sequence. These sequences had been shown essential for
effective expression from the HCV IRES (Reynolds et al., 1995). The
resulting spliced RNA has a reconstituted IRES sequence that is
capable of translating the 30 exon sequence (Fig. 2: step C).
Initial experiments were performed to select the most effectively
targeted uracils in the upstream regions of the HCV IRES [U160 (stem
loop IIIa), U194 (stem loop IIIb), U198 (stem loop IIIb), and U301 (stem
loop IIIe)]. These initial intron constructs contained ﬁreﬂy luciferase
(FLuc) as their 30 exon, and luciferase assays demonstrated signiﬁcant
levels of unintentional expression of FLuc in the absence of the target
sequence. These results suggested that the incomplete HCV IRES
sequence (up until stem loop IIIe) is still capable of initiat-
ing translation of the downstream coding sequence. The translation
efﬁciency with such incomplete constructs may not have been at
optimum levels but was enough to drive the expression of the 30 exon.
Such background expression would not be acceptable in downstream
applications using apoptosis-inducing genes, and this ﬁnding forced a
re-design to target uracils at a different position, speciﬁcally more
towards the 30 end of the HCV IRES.
We subsequently tested introns designed to target U329 (stem
loop IIIf) and U343 (stem loop IV) located at the very end of the
IRES sequence (Table 1, Fig. 3). Reconstituted IRES and down-
stream HCV core sequences from each of these uracils failed to
generate any detectable background FLuc expression with our
αHCV-GrpIs in the absence of target sequence. These targets
became our preferred targets for αHCV-GrpI construction.
Fig. 2. Group I intron-mediated trans-splicing mechanism. Group I intron base pairs with the target through the IGS and EGS. A nucleophilic 30-OH of an exogenous
guanosine attacks the phosphate backbone at the 50 splice site on the target RNA at the target Uracil and covalently binds to the excision product (A). While the P10 helix
brings the intron-attached 30 exon into a close proximity with the target Uracil, the free 30-OH of the cleaved Uracil attacks the 30 splice site (B). Resulting in a seamless
ligation of the target to the new 30 exon (C).
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The EGS of both introns were designed to base pair with the 50
terminus of the HCV core sequence, immediately followed by a short
stretch of a non-homologous loop bulge sequence (LB) to allow
efﬁcient formation of the P10 helix (Bell et al., 2004). We improved
the formation of the P1 helix in our introns by extending the IGS from
8 to 9 nucleotides and positioning the target uracil at nt 6 in this
sequence. We also improved the formation of the P10 helix and the
resulting splicing efﬁciency by making the last 3 nucleotides of the IGS
complimentary to the ﬁrst three nucleotides of the P10 helix
sequence. Insertion of two stop codons, UAA and UAG, immediately
50 of the intron UCG splice site insured that translation of the 30 exon
in the absence of splicing would not occur. Sequences that recon-
structed the 30 portion of the IRES from each of the target uracils along
with the ﬁrst 30 nt of the HCV core-coding sequence were inserted as
the last elements of each αHCV-GrpI.
HCV NS3/4A serine protease recognition site
To prevent illegitimate expression of the apoptotic gene products
from the 30 exon and to enhance the speciﬁcity of the apoptotic
reactions for HCV infected cells, we modiﬁed the pro-apoptotic forms
of BID, Caspase 3, and Caspase 8 by replacing their original cleavage
sites with the NS5A/5B cleavage recognition site for HCV NS3/4A HCV
serine protease. Inserting the sequence AEDVVCCCCSMSYS (NS5A/5B
cleavage site) at aa62 of BID, 25 and 172 of Caspase 3, and 211 (Hsu
et al., 2003) and 375 of Caspase 8 generated “pro” forms of these
apoptotic factors that could only be activated in the presence of the
HCV protease in infected cells, and therefore resulted in the initiation
of the apoptotic cascade. We chose to include the enzymes BID,
Caspase 3, and Caspase 8 apoptotic genes in addition to the non-
enzymatic tBax because their enzymatic properties enhance their
ability to induce apoptosis without relying upon apoptotic protein
buildup. The tBax has been reported to induce apoptosis more
efﬁciently than full-length Bax in vitro through a caspase-inde-
pendent mechanism (Usui et al., 2003; Carter et al., 2014).
αHCV-GrpIs mediate correct trans-splicing reactions in HCV infected
Huh7.5 cells
We examined each αHCV-GrpI for its ability to mediate the trans-
splicing reaction in infected Huh7.5 cells by RT-PCR. The purpose of
this assay was simply to prove that our introns are able to perform the
splicing reaction against the viral RNA in a qualitative manner. The
amount of unmodiﬁed HCV RNA species was not monitored because
this assay was not intended to be quantitative. Cells were transfected
with an intron-expressing plasmid (see Materials and methods and
Fig. 3) and challenged 48 h posttransfection with infectious HCV
Jc1FLAG2 at a MOI 0.1. Total cellular RNA was extracted at 72 h
postinfection and analyzed for spliced products by one-step RT-PCR.
The expected 400 bp spliced products were evident for both I19 and
I20 with each of the 30 exons; BID, Caspase 3, Caspase 8, or tBax, tested
(Fig. 4A: top). In contrast, spliced products were not detected in the
absence of RT (Fig. 4A: bottom) or from unchallenged cells expressing
the αHCV-GrpIs (Fig. 4B), conﬁrming the speciﬁcity of the trans-
splicing reactions for all the αHCV-GrpIs. In addition, control ΔIntrons
(Materials and methods), which lack the trans-splicing domain, failed
to produce spliced products (Fig. 4C), verifying that our αHCV-GrpIs
produce splice product via the trans-splicing mechanism. DNA
sequencing conﬁrmed correct splice junctions on all splice products
(Fig. 4D).
αHCV-GrpIs suppress IRES-dependent translation from HCV reporter
constructs in Huh7.5 cells
We utilized the Jc1FLAG2 construct containing the GLuc marker
gene inserted between p7 and NS2, as previously described (Marukian
et al., 2008), for all our luciferase assays. Full-length Jc1FLAG2 viral
RNA was generated by in vitro-transcription (Marukian et al., 2008)
and used to initiate infection in naïve Huh7.5 cells. The resulting
infectious virus-containing mediawas collected, titrated, and used as a
virus stock for downstream experiments. Huh7.5 cells were trans-
fected with plasmids expressing each of the αHCV-GrpI or control
plasmids at 48 h prior to HCV challenge at a MOI of 0.1. Supernatants
were collected at 72 h postinfection and the level of GLuc activity,
which correlates directly to the total amount of virus in infected cells,
was measured in each sample.
For these experiments we co-transfected a CMV promoted Cypri-
dina luciferase expression plasmid along with the intron to allow
normalization of the luciferase relative light unit (RLU) reads between
samples. The amount of GLuc activity in the untransfected control
infection was established as 100% for comparison purposes. As shown
in Fig. 5, our αHCV-GrpIs demonstrated varying levels of GLuc
knockdown in Huh7.5 cells, with I19C3 and I19tBax being the most
effective, reducing the level of GLuc activity to 20% of untransfected
control cells, followed closely by I9BID, 19C8, I20C3, and I20C8. I20BID
and I20tBx reduced GLuc to approximately 35% of untransfected
Fig. 3. Design of anti-HCV group I introns. Displaying I19 targeting U329 (top) and I20 targeting U343 (bottom). Target HCV and intron sequences are displayed in the 50-30
and 30-50 direction, respectively. The intron contains the following components in 50-30 direction: EGS, LB, IGS, trans-splicing domain, P10, reconstructed IRESþ30nt core
sequence, and 30 exon.
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controls. In contrast, the ΔΙntron control demonstrated only a slight
reduction in GLuc productivity to 80% of untransfected control cells.
Overall, these results demonstrated that the transfected αHCV-GrpIs
were able to effectively target HCV IRES RNA in infected Huh7.5 cells,
knocking down the level of GLuc activity by as much as 80%.
Repression of infectious virus production in αHCV-GrpI intron-
transfected cell cultures
Huh7.5 cell cultures were challenged at 48 h posttransfection with
HCV Jc1FLAG2 at MOI 0.1. Virus-containing cell supernatants were
collected 96 h postchallenge and virus titers were determined by IFA
(Fig. 6) in Huh7.5 cells. The anti-NS5A monoclonal antibody 9E10 was
used to stain infected cells (Lindenbach et al., 2005). Expression of
each αHCV-GrpI in Huh7.5 cells was expected to reduce the yield of
HCV following challenge with virus by eliminating productively
infected cells through apoptotic cell death.
In contrast to GLuc assays, the levels of virus suppression deter-
mined by TCID50 varied considerably between different introns. I19C3,
the most active intron observed in the GLuc assay, and I20BID was the
most effective in reducing the production of infectious virus from
intron-transfected cells, suppressing the infectious virus production by
more than 2 logs compared to the untransfected control cells (Fig. 6).
The I19tBax, which was as effective as I19C3 in GLuc reduction,
appeared to be less effective as measured by the TCID50 assay,
reducing the virus titer by slightly more than a log. The remaining
αHCV-GrpIs, I20C8, I20tBax, I19BID, I19C8, and I20C3 demonstrated
slightly lower suppression levels, reducing virus titers by approxi-
mately 1 log. In contrast, theΔIntron lacking the trans-splicing domain
did not demonstrate signiﬁcant inhibition of virus production.
Cell-speciﬁc cytotoxicity induced in infected Huh7.5 cells upon trans-
splicing
Huh 7.5 cells were transfected with each intron and subsequently
challenged with Jc1FLAG2 at 48 h posttransfection. Induction of
apoptosis following HCV-challenge of αHCV-GrpI expressing cells
was visualized by Annexin V-FITC staining at 48 h postinfection. The
percentage of apoptotic cells was reported based on the numbers of
ﬂuorescent positive cells counted from four separate ﬁelds divided by
the total cell count.
Cultures expressing the αHCV-GrpIs consistently exhibited greater
numbers of ﬂuorescing cells than the infected control culture when
challenged with HCV (Fig. 7A). These results suggested that apoptosis
was in fact induced in the intron expressing cells upon virus infection.
The ΔIntron lacking the trans-splicing domain exhibited a similar
percentage of ﬂuorescent cells as the infected control culture, indicat-
ing that the ﬂuorescence observed in the αHCV-GrpI cultures was a
result of targeted splicing by the αHCV-GrpIs and induction of
apoptosis through translation of the splice product, and not some
other non-speciﬁc effect such as antisense-mediated induction.
Among the 30 exons tested, Caspase 3 and tBax were found to be
the most effective in inducing apoptosis, bringing the total count of
Fig. 4. Splice product detection by RT-PCR. Total RNA was extracted from HCV infected cells at 48 h and the spliced products were detected by RT-PCR. (A) Top: introns cells,
þreverse transcriptase (RT); bottom: RT; (B) mock and uninfected intron cells; (C) Δintrons containing only guide sequences. Arrow indicates splice product and (D) DNA
sequencing of the splice junction. Bordered indicates Uracil target.
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Fig. 5. Luciferase assay. Huh7.5 cells were transfected with each intron 48 h prior
to full-length, HCV-GLuc infection. Samples were collected at 72 h and measured
for GLuc activity. GLuc measured for the control wild-type cells (Wt) was set to
100% for comparison with each intron. ΔI: intron lacking a trans-splicing domain
containing only guide sequences. The error bars represent standard error of the
mean computed from three independent experiments.
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apoptotic cells signiﬁcantly higher than those of the control cells
without the virus infection (Fig. 7B).
Elevated Caspase 3 activity in infected Huh7.5 cells upon trans-
splicing
To insure cellular apoptosis upon intron trans-splicing to the HCV
genome we designed the 30 exon to express the apoptotic-inducing
genes BID, Caspase 3 and Caspase 8, in their proactive form. As added
insurance against apoptotic activity in the absence of HCV infection,
we substituted the native activation cleavage sequence for each of the
proactive forms with the HCV NS3/4A protease cleavage sequence. As
a control for apoptosis induction without proteolytic cleavage we also
included the previously utilized, apoptotically active tBax coding
sequence (Toyota et al., 2006). The BID and tBax proteins are involved
in cytochrome-C release from the mitochondria while Caspase 3 and
Caspase 8 cysteine proteases are involved in the execution phase of
the cascade (Antonsson and Martinou, 2000).
Huh7.5 cells were transfected with each intron and challenged at
48 h posttransfection with HCV Jc1FLAG2, and the effectiveness of
apoptosis induction was measured using a Caspase 3 assay
(Thornberry and Lazebnik, 1998). As demonstrated in Fig. 8, the level
of Caspase 3 activity was signiﬁcantly increased in the I19C3 and
I20C3 cells (þvirus) compared to their respective negative controls
(virus). However, the Caspase 3 induction was most robust with
I19tBax, which exhibited a difference of almost 6-fold between
unchallenged and virus challenged cells. Surprisingly, the I-BID and
I-Caspase 8 only induced Caspase 3 activity to a level comparable with
the control wild-type cells. As expected, the ΔIntron did not exhibit a
signiﬁcant increase of Caspase 3 activity. The low amount of activated
Caspase 3 observed in theΔIntron and control cells may be attributed
to cell death caused by DNA transfection procedures and/or the effect
of a typical HCV infection. Together, these results indicated that
Caspase 3 and tBax are the two best options as 30 apoptotic exons
among the four tested.
αHCV-GrpIs do not induce phosphoprylation of PKR
Double-stranded RNA formation through complementary base
pairing of the ΔIntron EGS and the target viral RNA may trigger the
activation of PKR activity resulting in the reduction of the viral protein
synthesis (Qashqari et al., 2013). We examined the possibility that the
slight anti-HCV effect observed for ΔIntron transfected cells (Fig. 5)
might be due to the activation of a speciﬁc PKR response. Cell lysates
collected at 96 h postinfection were assayed for PKR activity using
Western blot analysis. However, we observed no signiﬁcant difference
in the level of PKR and phospho-PKR between the intron transfected
cells and ΔIntron transfected cells (Fig. 9). These results do not
support the possibility that the slight knockdown of the GLuc level
observed for ΔIntron (Fig. 5) was caused by the activation of a PKR
response, but rather by some inherent variation in the transfection
procedure.
Discussion
HCV is one of the leading causes of hepatocellular carcinoma, liver
cirrhosis and liver transplantations in the United States (Belousova
et al., 2015; Rosen 2011). Novel strategies have been developed to
combat the virus with different levels of success. Some of the
approaches that are relevant to our research include the use of
antisense (Gonzalez-Carmona et al., 2011; Jarczak et al., 2005; Korf
et al., 2005), siRNA (Zekri et al., 2009), aptamer (Kikuchi et al., 2005;
Nishikawa et al., 2003), hammerhead ribozyme (Gonzalez-Carmona
et al., 2006) and group I intron (Ryu et al., 2003). Due to the high
error-prone rate of the virus RdRp, target site selection is of utmost
importance for these effector molecules to be effective against virus
quasispecies. In our initial analysis of the virus 50 UTR, we observed
that the sequence of the HCV IRES, one of the most characterized
region on the virus genome, is well conserved among genotypes.
Therefore, it represents a potential target region for RNA-based anti-
viral inhibitor strategies. Since the IRES has a crucial function in both
viral translation and replication processes required for viral main-
tenance and propagation, disrupting the IRES structure will result in
interruption of both processes.
Group I introns have been used to target the HCV IRES successfully
in liver cells using an in vitro-transcribed artiﬁcial target (Ryu et al.,
2003). However, the previous study implemented the use of the
Diphtheria toxin gene as their 30 exon which causes concern for the
safety of such approach for human gene therapy. Our study differs in
that we used naturally occurring apoptosis-inducing genes, eliminat-
ing the necessity for any type of bacterial toxin. In addition, our
apoptotic genes may only be activated in the presence of active HCV
virus, while uninfected cells will remain unaffected.
In this study we examine the effectiveness of two anti-viral group I
introns against HCV. These introns, I19 and I20, target the highly
conserved U329 of the domain IIIf and U343 of the domain IV in the
IRES, respectively, both of which are required for proper translation
initiation of the viral proteins. These introns are further modiﬁed from
the original intron sequence to include an extended complimentary
EGS, IGS, and P10 helix to increase the intron splicing efﬁcacy (Carter
et al., 2010). The downstream sequence of the HCV IRES that follows
the target site is also included to regenerate the complete IRES stru-
cture upon splicing.
The group I intron catalytic sequence itself is immediately followed
by one of the cell death-inducing apoptotic genes, BID, Caspase 3,
Caspase 8, or tBax, as the 30 exon. These apoptotic 30 exons are
constructed in-frame with 30 nt of the HCV core-coding sequence.
This sequence has been deﬁned as essential for proper translation
initiation from the HCV IRES sequence and is necessary for optimal
expression of the 30 exon encoded proteins (Kohara et al., 1992).
When properly spliced, the resulting RNA encodes a fusion protein
that induces cell death. The effect on viral suppression is therefore
2-tier; cleavage by the intron destroys the target virus genome, while
splicing simultaneously induces cytotoxicity in the infected cells. This
approach should have advantages over antisense oligonucleotide,
siRNA, or simple target-cleaving ribozyme strategies where viral
RNA is simply cleaved or blocked for translation.
Inappropriate initiation of translation or off-target splicing result-
ing in expression of these apoptotic factors is an undesired outcome
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Fig. 6. TCID50 titration assay. Huh7.5 cells were transfected with each intron 48 h
prior to full-length, HCV-GLuc infection. Samples were collected at 96 h and the
viral titers were determined by TCID50. Wt: wild-type cells, ΔI: intron lacking a
trans-splicing domain. Data represented in the scale of Log 10. The error bars
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Fig. 7. Apoptotic cell death visualized by Annexin V staining. (A) HCV-infected cells were stained with Annexin V at 48 h postinfection. Left: cells visualized under a
ﬂuorescent ﬁlter; Right: under a bright ﬁeld; (B) Positive Annexin-V-stained cells were counted and divided by total cell count. For each sample, cells were counted manually
from 4 separate ﬁelds; Wt: wild-type cells; ΔI: intron lacking a trans-splicing domain; þvirus: with virus; virus: without virus.
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for this strategy. Two stop codons are added in-frame immediately 30
of the intron splicing domain and prior to the intron splice junction to
prevent illegitimate translation of the 30 exon. Further insurance is
provided in the case of the BID, Caspase 3, and Caspase 8 constructs by
incorporating them as modiﬁed proactive forms in which their
endogenous cleavage sites are replaced with the HCV protease
NS5A/5B cleavage site (Hsu et al., 2003). This strategy ensures that
unintended splicing and illegitimate expression of the toxic 30 exon in
the absence of the HCV infection is not possible.
Using RT-PCR with primers speciﬁc for the spliced product
sequence, the targeting and trans-splicing capabilities of each intron
are demonstrated against viral target RNA in transfected Huh7.5 cells,
with splice junctions conﬁrmed by sequence analysis. The negative
control ΔIntron lacks any detectable splicing activity, and serves as a
control for the anti-viral interfering effect, if any, resulting from IGS
and EGS homologous interactions with the viral IRES sequence. These
experiments are designed to detect predicted splice products in HCV
infected cells expressing functional introns but cannot detect potential
off-target cleavage or splicing. However, based upon the extent of
sequence homology required for the speciﬁc interactions that would
lead to splicing we would expect off-target events to be extre-
mely rare.
The ability of the introns to reduce the production of virus in
infected cell cultures was assessed using the Jc1FLAG2 recombinant
HCV that expresses the GLuc marker gene inserted between p7 and
NS2 on the target viral genome. A decreased level of GLuc activity
indicates reduced viral RNA production. The GLuc assay demonstrates
virus knockdown for all our intron vs. non-intron (wild-type) cells
especially for I19C3 and I19tBax where 80% knockdownwas observed.
The level of knockdown seen in our study is comparable to a previous
aptamer study (Romero-Lopez et al., 2012) but considerably higher
than the previous group I intron study in which only 50% knockdown
of luciferase was reported (Ryu et al., 2003). The insigniﬁcant, slight
knockdown observed for the ΔIntron suggested that the presence of
the intron in the cells may have had a small effect on virus production.
This observation could not have resulted from illegitimate expression
of the 30 apoptotic exon because the ΔIntron is not capable of trans-
splicing, as demonstrated by the RT-PCR results (Fig. 4A–D). In
addition, the knockdown does not appear to be related to activation
of a PKR response since there was no signiﬁcant difference in the PKR
level observed between the I19C3, I19tBx intron and their correspond-
ing ΔIntrons. The most likely explanation for this result is inherent
variation in the transfection procedure.
HCV-challenged intron expressing cells were also analyzed by
TCID50 to determine the level of suppression of infectious virus
production. The results among our introns are less uniform than the
GLuc assay.We observed that the level of suppression ranged between
1 and 3 logs, with I19C3 being the best effector among all introns
tested, bringing down the infectious virus titer to almost 1000 fold
(3 logs) compared to the non-intron cells. The ΔIntron control
conﬁrms our observation that expression of the intron constructs
did affect infectious virus production.
The presence of cell death upon splicing is veriﬁed by Annexin V
staining. Although the HCV-infected wild-type cells exhibit a small
number of ﬂuorescent cells, the effect is considered insigniﬁcant
compared to what we observe in cells expressing the apoptosis-
inducing introns, where cells undergoing apoptosis are observed in
almost every ﬁeld and with a much greater ﬂuorescent intensity.
When examined with bright ﬁeld, wild-type cells maintain a healthy
cell morphology and grow to conﬂuence. The intron expressing cells,
however, exhibit cell changing characteristic of apoptosis such as cell
shrinkage and blebbing. There is no evidence of cell death in the
ΔIntron expressing control cells indicating that apoptosis events in the
intron expressing cells result from correct trans-splicing reactions.
We quantiﬁed the level of apoptosis by indirectly measuring
the level of Caspase 3 activity in infected cells. To facilitate
quantitative comparison, since the amount of cells was lower in
the intron cells than wild-type, we corrected the ﬂuctuation of the
Caspase 3 between samples by calculating its activity on a per cell
basis. Similar to the results shown in the Annexin V staining, an
insigniﬁcant background level of Caspase 3 is evident in the
control wild-type and ΔIntron cells, with or without the virus.
The intron expressing cells, on the other hand, exhibit a signiﬁcant
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Fig. 9. Western blot analysis. Total proteins were extracted at 96 h postinfection
and immunoblotted for PKR, phospho-PKR, and β-actin. While untransformed cells
infected with HCV (I-Wt) showed relatively high levels of both PKR and phospho-
PKR, there was no signiﬁcant difference evident in the concentration of PKR or
phospho-PKR between cells transformed with 19C3, I19tBx, and ΔI group I introns.
(þ): IFN-induced positive control wild-type cells; Wt: untransformed, uninfected
wild-type cells; I-Wt: HCV-infected untransformed wild-type cells, ΔI: intron
lacking a trans-splicing domain.
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increase in the level of Caspase 3, especially for I19C3 and I20C3
where the Caspase 3 levels are 3 times higher than their respective
backgrounds without virus, or twice higher than the control wild-
type cells. The 19tBx do not express the same level of total
knockdown but display the most robust activation of Caspase
3 in these cells. In fact, the level of activated Caspase 3 is almost 6-
fold higher than its respective background level without the virus.
These results suggest that a robust induction of apoptotic cell
death occurred within our intron expressing cells.
We have demonstrated the effectiveness of IRES-targeting αHCV-
GrpIs in inhibiting viral replication in vitro. These results were obt-
ained utilizing transient experiments where the intron constructs
were introduced into the cells through chemical transfection. Based
on our previous published data (Carter et al., 2010; Nawtaisong et al.,
2009), we expect to see a higher suppression effect when we have
established clonal cell population of our introns. Due to the structural
conservation in the IRES region among various HCV strains, our group
I intron approach should be applicable to other HCV strains not tested
in our study. The combination of more than one individual introns or a
single chimeric intron simultaneously attacking different sites on the
target virus may offer a different approach to better combat the virus.
Alternatively, the intron may be designed to include an aptamer
region to increase the splicing efﬁcacy and speciﬁcity and to avoid
viral escape mutants since aptamers rely on structural than sequence
recognition of the target virus (Kikuchi et al., 2005; Romero-Lopez
et al., 2012). Our current strategy may also prove to be useful when
combined with other antiviral-based strategies and/or current and
future drug treatments to completely eradicate the disease.
Materials and methods
Target site selection
Genome sequences of most known HCV quasispecies were
obtained from the Los Alamos Hepatitis C Sequence Database
(Kuiken et al., 2005) and aligned in ClustalX (Thompson et al., 1994).
The aligned sequences comprise the following GenBank GenInfo
identiﬁers: 22129792, 9843676, 21397075, 21397076, 21397077,
8926244, 221586, 2327072, 2327074, 2316097, 2327070, 329873,
329737, 221604, 221606, 20521945, 2943783, 3098638, 15529110,
12831192, 1944375, 14581919, 11559440, 11559442, 11559444,
11559446, 11559448, 11559450, 11559452, 11559454, 11559456,
11559458, 11559460, 11559462, 11559464, 11559466, 11559468,
1212741, 560788, 306286, 27544243, 7650221, 7650223, 7650225,
7650227, 7650229, 7650231, 7650233, 7650235, 7650237, 7650239,
7650241, 7650243, 7650245, 7650247, 7650249, 7650251, 7650253,
7650255, 7650257, 7650259, 7650261, 7650263, 7650265, 7341102,
3098634, 3098636, 3098632, 2764397, 48237633, 471116, 38492204,
329739, 5420376, 4753718, 4753720, 1181831, 329770, 221610,
1030706, 1030705, 1030701, 1030702, 1030704, 1030703, 23957856,
960359, 385583, 62006146, 1160327, 59478, 221612, 221614, 5918928,
5918930, 5918964, 5918966, 5918932, 5918934, 5918936, 5918938,
5918940, 5918942, 5918944, 5918946, 5918948, 5918950, 5918952,
5918954, 5918956, 5918958, 5918960, 5918962, 567059, 437107,
46560633, 5738246, 19568932, 2443428, 329763, 464177, 15422182,
50235321, 6707281, 6707283, 7329200, 7329202, 7329204, 7329206,
7329208, 6707279, 6707285, 6010579, 53680893, 53680893, 221650,
13122263, 13122265, 13122267, 13122269, 13122271, 13122273,
13122261, 9757541, 7329210, 221608, 1483141, 6521008, 2895898,
558520, 514395, 633201, 676877, 1183032, 2252489, 2464303,
3660725, 60115454, 60115455, 1183030, 60115457, 62362179, and
60115456. These sequences cover all major HCV genotypes including
1a, 1b, 1c, 2a, 2b, 2c, 2k, 3a, 3b, 3k, 4a, 5a, 6b, 6d, 6g, 6h, and 6k. The
IRES is located in the 50 UTR of the virus genome and continues to 40
nucleotides of the core-coding sequence (Reynolds et al., 1995). Target
Uracils for Intron 19 (I19) targeting domain IIIf and Intron 20 (I20)
targeting domain IV are U329 and U343, respectively.
Addition of HCV NS3/4A serine protease recognition site to pro-
apoptotic factors
Apoptotic factors BID and Caspase 3 were modiﬁed by replacing
their endogenous cleavage sites (aa62 in BID and aa25 and 172 in
Procaspase 3) with the NS3/NS4A recognition site NS5A/NS5B clea-
vage sequence: AEDVVCCCCSMSYS (Hsu et al., 2003). For Caspase 8,
the 50 end was truncated at aa186 in the Procaspase 8 and the NS5A/
5B recognition sequence was inserted at aa211 and 375. These
complete pro-apoptotic genes were synthesized by GeneArt (Life
Technologies, USA) with nucleotide usage optimized preferably for
mammalian expression.
Anti-HCV group I intron constructs
The sequence of group I intron splicing domain used in this study
was derived from the catalytic core of the rRNA Tetrahymena thermo-
phila on the pTT1A3-T7 plasmid (a kind gift from Dr. Thomas Cech,
University of Colorado, Boulder). In the preliminary assay (Fig. 1C), we
constructed a set of introns attacking an artiﬁcial target that encoded
the HCV IRES linked to a Fluc-reporter sequence. Cleavage of the HCV
IRES sequencewould result in a reduction of FLuc expression. Oncewe
had determined the best attack site, we constructed our αHCV-GrpI
introns based on the sequences surrounding that target site. The I19
and I20 were generated by PCR ampliﬁcation using the follo-
wing primer sets: I19 for: 50GTTAACTTTTCTTTGAGGTTTAGGAT-
TCGTGCTCATGCAGTCGGTCTGCGAGAAAAAGTTATCAGGCATGCACCTG-
GT30; I19 rev: 50ACCGGTTTTTCTTTGAGGTTTAGGATTCGTGCTCATGG
TGCACGGTCTCGATTAGTACTCCAAAACTAATCAATATACTTTC30; I20 for:
50GTTAACTTTTCTTTGAGGTTTTCCTAAGGTGCTCGTGGTAAAAGTTATCA-
GGCATGCACCTGGT30; and I20 rev: 50ACCGGTTTTTCTTTGAGGTTTAG-
GATTCGTGCTCCGATTAGTACTCCAAAACTAATCAATATACTTTC30. The
forward primers contain EGS, IGS, and 50 end of the intron splicing
domainwhile the reverse primers contain 30 end of the intron splicing
domain, P10 helix, Loop Bulge (LB), reconstructed 30 and an extended
30 nt-long core sequence (Table 1). Following PCR ampliﬁcation and
band isolation, the introns were restriction digested with HpaI and
AgeI and inserted into a backbone vector pLRH (Nawtaisong et al.,
2009). The CMV promoter driving the expression of the intron was
obtained by PCR ampliﬁcation of the pCMV-DsRed-Express (Clontech,
USA) using forward: 50GGATCCTCAATATTGGCCATTAGCCATA30 and
reverse: 50GTTAACCCTATAGTGAGTCGTATTAA30 primers and was
digested and inserted into the backbone vector at BamHI and HpaI
sites. The 30 apoptosis-inducing exon BID, Caspase 3, Caspase 8, or
tBax was ampliﬁed by PCR ampliﬁcation of the templates synthesized
Table 1
Positions of target Uracils within the HCV IRES and sequences of group I intron domains. EGS, External Guide Sequence; IGS, Internal Guide Sequence; P10, P10 helix; LB,
Loop Bulge.
Version Target U EGS IGS P10 LB Reconstructed IRESþcore
I19 U329 ttttctttgaggtttaggattcgtgctcatg cggtctgcgaga agaccg cagt tgcaccatgagcacgaatcctaaacctcaaagaaaa
I20 U343 ttttctttgaggttt gtgctcgtggtg gagcac tcctaag gaatcctaaacctcaaagaaaa
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by MR. GENE using the following primers: BID for: 50ACCGGTATG-
GACTGTGAGGTC30and rev: 50ATGCATCTATTAGTCCATCCCATTTCTGG30;
Caspase 3 for: 50ACCGGTATGGAGAACACTGAAAAC30 and rev:
50ATGCATCTATTAGTGATAAAAATAGAGTTCTTTTGTG30; Caspase 8 for:
50ACCGGTATGGGGGAGGAG30 and rev: 50ATGCATCTATTAATCAGAA-
GGGAAGACAAG30; tBax for: 50ACCGGTGCCCTTTTCTACTTTGCCAGCA30
and rev: 50ATGCATCTAGCCCATCTTCTTCCAGATGG30. These apoptotic
genes were inserted into the vector between AgeI and NsiI sites. The
resulting introns were named I19BID, I19C3, I19C8, I19tBx, I20BID,
I20C3, I20C8, and I20tBx. To create inactive control introns (ΔIntrons),
the entire splicing domain was removed, leaving only the EGS, IGS,
P10, LB and 30 exon to religate.
Huh7.5 cell culture
All cell culture experiments were carried out in Huh7.5 human
hepatocellular carcinoma cells (a kind gift from Dr. Charles Rice, the
Rockefeller University, USAwith written permission from Apath). Cells
were routinely maintained in Dulbecco's Modiﬁed Eagle's Medium
(DMEM; Sigma-Aldrich, USA) supplemented with 2 mM L-glutamine
(Sigma-Aldrich, USA), 10% heat-inactivated fetal bovine serum (FBS;
Sigma-Aldrich, USA), and 1 non-essential amino acids (Gibco; Life
Technologies, USA) and incubated at 371C in a 5% CO2 atmosphere.
DNA transfection
Cells were plated in 6-well plates at 6105 cells/well 24 h before
transfection. We used Lipofectamine LTXþPlus reagent system (Life
Technologies, USA) for all DNA transfection experiments. Transfection
reaction was prepared by combining the following components: 1 mg
intron plasmid DNAþ10 ml Plus reagentþ50 ng Cypridina plasmid
DNA (as a normalizer; in the luciferase assay; NEB, USA)þ100 ml
serum-free optiMEM (Life Technologies, USA). The reaction was
incubated at RT for 15 min followed by addition of 100 ml of 5%
Lipofectamine LTX (5 ml LTX diluted in 95 ml serum-free optiMEM).
The DNA:Lipofectamine LTX complex was allowed to form at RT for
30 min. DMEM was then added to the reaction to make up to 1 ml
total volume. Cells were left in transfection media for 24 h at
37 1Cþ5% CO2 before replacing with fresh DMEM. Transfected cells
were allowed to grow for another 24 h prior to virus inoculation.
Jc1FLAG2 HCV transcription
The Jc1FLAG2 plasmid (a kind gift from Dr. Charles Rice, the
Rockefeller University, USA; (Lindenbach et al., 2005)) encoding a
full-length HCV was used to generate a transcription template as
previously described (Lindenbach et al., 2005). Brieﬂy, 10 mg of the
plasmid was digested with XbaI for 3 h at 37 1C and cleaned up using
the Wizard SV Gel and PCR Clean-Up System (Promega,USA). The T7
RiboMAX Express Large Scale RNA Production System (Promega, USA)
was used for a transcription reaction of 1 mg DNA template. The
reaction was incubated for 30 min at 37 1C. One U of supplied DNase
was then added to eliminate the DNA template. The reaction was
incubated for an additional 15 min at 37 1C. The ﬁnal RNA transcript
was cleaned up and eluted in the RNA storage solution (Ambion; Life
Technologies, USA) using the Qiagen RNeasy kit (Qiagen, USA). The
puriﬁed RNA was aliquoted for single uses and stored frozen
at 80 1C.
Full-length infectious Jc1FLAG2 HCV preparation
Huh7.5 cells were washed twice before electroporation. In a multi-
well electroporation plate (4 mm, 25 wells; BTX Harvard Apparatus,
USA), 5106 cells were mixed with 10 mg RNA, loaded onto each well
(in total volume 400 ml) and electroporated using the BTX Electro-
Square Porator ECM 830 (BTX Harvard Apparatus, USA) with the
following settings: 860 V, 5 pulses, 99 ms, 1.1 s interval, and high
voltage. Electroporated cells were plated immediately after. Virus-
infected cells were incubated at 37 1Cþ5% CO2. Virus-containing
media was harvested every 4 h for up to 96 h, clariﬁed by ﬁltration,
and concentrated using the Stirred Ultraﬁltration Cell system (Model
8400; Millipore, USA). Concentrated virus was aliquoted into cryo-
tubes for single uses and stored at 80 1C. Virus titer was determined
by TCID50 titration (see below).
HCV infection and sample collection
Cells were washed once with DMEM, followed by HCV inoculation
at MOI 0.1. The inoculum was removed at 6 h. Cells were washed
twice and replenished with 2 ml DMEM. Virus-containing super-
natants were collected at 48 h (for apoptosis assay), 72 h (for luciferase
assay), or 96 h (for TCID50) and ﬁltered through a sterile 0.45 mm
cellulose acetate syringe ﬁlter. Supernatants were stored frozen at
80 1C until assayed. For Annexin V staining, cells were stained at
24 h postinfection.
One-step RT-PCR
Splice products were detected by RT-PCR, followed by DNA
sequencing to conﬁrm the correct sequence of the splicing junctions.
Total RNA was extracted from infected and uninfected cells using
TRIZol Reagent (Life Technologies, USA) following the manufacturer's
instructions without modiﬁcation and eluted in 100 ml nuclease-free
water. RNA quantity and purity were measured by Nanodrop (Ther-
moScientiﬁc, USA). Superscript III One-Step RT-PCR System with
Platinum Taq High Fidelity kit (Life Technologies, USA) was used for
all RT-PCR reactions. Brieﬂy, the RNA was treated with TURBO DNA-
free DNase (Ambion; Life Technologies, USA) for 30 min at 37 1C to
remove any DNA residues. To deactivate DNase, 0.1 volume of DNase
Inactivating reagent was added to the reaction and incubated at RT for
5 min with periodic mixing. The RNA was collected after centrifuga-
tion at 10,000g for 1.5 min. Ten micrograms of DNA-free RNA was
transferred to the RT-PCR reaction. The spliced product was detected
using “splice primers” speciﬁc to the target (forward) and 30 exon
(reverse) that straddle the splice junction. The RT-PCR proﬁle was as
follows: 50 1C 45 min for cDNA synthesis, 94 1C 2min, 40 cycles of
94 1C 15 s, 59 1C 30 s, and 68 1C 1min, and 68 1C 7min. PCR products
were run on 0.9% agarose gel, followed by band visualization using the
Gel Doc EZ Imager (Bio-Rad, USA) and band isolation using theWizard
SV Gel and PCR Clean-Up System (Promega,USA). Correct spliced
products were conﬁrmed by DNA sequencing (Genomics Core Facility,
University of Notre Dame, USA).
Fireﬂy luciferase assay (FLuc assay)
Transfected cells were washed twice with PBS before addition of
350 ml of 1 Lysis Buffer. Cells were incubated at RT for 5 min and
transferred to a microcentrifuge tube for storage at 80 1C overnight.
The next day, frozen cells were freezed and thawed repeatedly 3 times
and centrifuged at 10,000rpm for 2 min. Fireﬂy Relative Units (FRUs)
were read on 20 ml sample in a 96-well format after addition of 100 ml
of Luciferase Assay Reagent (Promega, USA). Relative light units (RLUs)
were measured with a spectramax plate reader (L MAXII 384,
Molecular Devices, USA). Luminescence was integrated over 100 s
with a 3-s delay.
Gaussia luciferase assay (GLuc assay)
Collected supernatants were immediately mixed with an equal
amount of 1 lysis buffer. 20 ml of lysed sample was loaded on to a
96-well plate in triplicate. Gaussia luciferase (GLuc) activity was
detected using the Renilla Luciferase Assay System (Promega, USA).
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Relative light units (RLUs) were measured with a spectramax plate
reader (L MAXII 384, Molecular Devices, USA). Luminescence was
integrated over 10 s with a 2-s delay and measured upon injection of
50 ml of substrate reagent. For Cypridina luciferase (normalizer)
measurement, we used BioLux Cypridina Luciferase Assay kit (NEB,
USA) with identical settings to GLuc measurement except we set the
integration time to 2 s.
TCID50 assay
The titers of infectious HCV in infected cell culture supernatants
were measured by immunohistochemistry staining in conjunction
with an endpoint dilution assay as previously described (Lindenbach
et al., 2005). Brieﬂy, a 10-fold serial dilution of the virus-containing
supernatants was performed and used to infect Huh7.5 cells in
multiple wells of 96-well plates. Infection was allowed to incubate
for 96 h at 37 1Cþ5% CO2. Infected cells were then washed with PBS
and ﬁxed with freezer-cold methanol for 30 min at 20 1C. Cells were
blocked in PBSþ1% BSAþ0.2% skim milk for 30 min, followed by
staining with the NS5A-speciﬁc 9E10 primary antibody (diluted at
1:2000; a kind gift from Dr. Charles Rice, the Rockefeller University,
USA; (Lindenbach et al., 2005) for 1 h. Endogenous peroxidase was
quenched with 3% H2O2 for 5 min and cells were incubated with a
secondary antibody from the ImmPRESS Anti-Rabbit Ig (peroxidase)
Polymer Detection kit (diluted at 1:3; ImmPRESS; Vectorlab, USA) for
30 min. HCV-infected cells were visualized under light microscope
after addition of peroxidase DAB substrate (diluted at 1 drop/ml of
supplied buffer; DABþ; Dako, USA) for 1 h. The 50% tissue culture
infectious dose (TCID50) was calculated using Reed & Muench's
protocol (Reed and Muench, 1938).
Caspase 3 activity assay
At 48 h postinfection, cells were trypsinized, pelleted, washed with
PBS, and counted. The Caspase 3 activity was measured using the
EnzChek Caspase-3 Assay Kit 2 (Life Technologies, USA) in accordance
with the manufacturer's instructions. Brieﬂy, cells were lysed on ice
for 30 min in 50 ml cell lysis buffer. Following pelleting of cell debris at
5000 rpm for 5 min, 50 ml supernatant was combined with 50 ml of
the 2 substrate working solution. The reaction was incubated in the
dark for 30 min. The ﬂuorescence was measured using a ﬂuorescence
plate reader (SPECTRAmax M2, Molecular Devices) with the following
settings for excitation/emission: 496/520 nm. The RFUs readout for
each sample was calculated on a per cell basis.
Annexin V staining
Apoptotic cells were visualized using the Annexin V-FITC Apoptosis
Kit Plus (MBLI, USA). Brieﬂy, cells were stained with 5 ml Annexin V-
FITC diluted in 500 ml 1 Binding buffer for 10 min in the dark at RT.
Apoptotic cells were visualized with a GFP ﬁlter. Total cells were
counted and the percentage of positive cells were calculated.
Western blot analysis
At 96 h postinfection, cell extracts were prepared in RIPA buffer
supplemented with Halt Protease Inhibitor Cocktail (Thermo Scientiﬁc,
USA) and phenylmethylsulfonyl ﬂuoride (PMSF; Thermo Scientiﬁc,
USA). The extracted proteins were sonicated for 15 s twice at 50%
pulse and then mixed with 1.25% β-mercaptoethanol and 1:3 volume
LDS Sample Buffer (Thermo Scientiﬁc, USA) before boiling for 5 min.
The protein concentrations in the samples were measured using
NanoDrop and 12 mg of proteins were separated by 10% SDS-PAGE
and transferred onto nitrocellulosemembranes by electroblotting with
an XCell SureLock unit (Life Technologies, USA). The protein blots were
blocked overnight at 4 1C with PBSþ5% non-fat milk (NFM) and
incubated with polyclonal anti-PKR (Santa Cruz, USA), monoclonal
anti-pPKR (Abcam, USA), or polyclonal anti-β-actin (Thermo Scientiﬁc,
USA) diluted at 1:1000 in PBS-Tþ0.5% NFM for 1 h at room tempera-
ture with agitation. After incubation, the membranes were washed for
5 min (4) with PBS-T and incubated with a 1:1000 dilution of
donkey anti-rabbit IgG-HRP (Santa Cruz, USA) in PBS-T þ0.1% NFM for
1 h at room temperature with agitation. The membranes were washed
again for 5 min (4) with PBS-T and developed using the SuperSignal
West Dura Chemiluminescent Substrate (Thermo Scientiﬁc, USA) for
5 min at RT. Immunoreactive bands were detected by exposing the
membranes to X-ray ﬁlm. As a positive control, untransformed wild-
type cells were infected and induced with Human Interferon Beta 1α
(PBL Assay Science, USA) at 100 U/ml concentration for 16 h prior to
protein extraction (Garaigorta and Chisari, 2009).
Statistical analysis
For reproducibility, each assay was performed in triplicates.
Data were analyzed in Prism6 software (GraphPad, USA). Statistical
signiﬁcance (p-Value o0.05) between the intron-transfected cells
vs. control cells were reported along with standard errors of
the means.
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